Anthelmintic Drugs Market By Drug Class (Benzimidazoles, Macrocyclic Lactones, Pyrazinoisoquinolones, Tetrahydropyrimidines, Others), By Infection Type (Cestode Infections, Nematode Infections, Trematode Infections, Mixed Infections), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032
The global anthelmintic drugs market was valued at $1.0 billion in 2022, and is projected to reach $1.5 billion by 2032, registering a CAGR of 3.8% from 2023 to 2032. Anthelmintics are medications used to treat parasitic worms, also called helminths, which can cause infections in humans. Helminths can cause various diseases and health problems. Anthelmintics work by killing or inhibiting the growth and reproduction of the parasites in the host’s body. Anthelmintics target various types of parasites, such as nematodes, tapeworms, cestodes, and flukes. These drugs are used to control and eliminate parasitic worms. They can be used as preventive or therapeutic measures depending on the type and severity of the parasite. The type of Anthelmintic prescribed by a healthcare provider depends on the type and location of the worm infection, as well as the overall health status of the patient.
Anthelmintic drugs play an essential role in global health initiatives due to the global prevalence of parasitic worm infections, which affect millions of people around the globe. These infections are caused by nematode, trematode, and cestode, and are particularly prevalent in countries with poor sanitation and lack of access to healthcare. In many developing countries, soil-transmitted (STH) helminths such as roundworm, whipworm, and hookworm are endemic. These infections cause serious health problems, particularly in children, which can affect their growth, cognition, and quality of life.
For instance, according to an article published by National Centre for Biotechnology Information (NCBI) in 2021, globally there are around 3.5 million people affected with intestinal parasitic infections, and more than 200,000 deaths are reported annually. Such incidences of such parasitic infections are increasing the need for anthelmintic, which propels the market growth. In addition, there are also zoonotic infections, which are transmitted by animals to humans and can lead to serious health problems, such as hydatid disease which is a complication of the tapeworm. Combating these infections not only benefits the individual, but also contributes to the well-being of the community, increases economic productivity, and improves the quality of life.
In addition, there is an increase in government expenditure and investment in healthcare infrastructure, including the allocation of funds to treat and prevent various diseases, such as parasitic worm infections, owing to economic growth in emerging economies. There is an increase in availability of affordable and accessible anthelmintic drug for the population owing to increased financial resources for healthcare. Economic growth often leads to improved access to healthcare facilities, such as clinics, hospitals and pharmacies. This improved accessibility means that people living in rural or poor areas, where the prevalence of parasitic infections may be higher, can now visit healthcare facilities to be diagnosed and treated for these conditions. The demand for anthelmintic drugs increases as more people can access healthcare facilities.
The anthelmintic drugs market is segmented on the basis of drug class, infection type, distribution channel, and region. On the basis of drug class, the market is divided into benzimidazoles, macrocyclic lactones, pyrazinoisoquinolones, tetrahydropyrimidines and others. On the basis of infection type, the market is classified into nematode infections, cestode infections, trematode infections and mixed infections. Based on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.
Major players profiled in this report are GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Bayer AG, Cipla Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Reese Pharmaceutical Company, and Zydus Lifesciences Limited.
Key Benefits for StakeholdersThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anthelmintic drugs market analysis from 2022 to 2032 to identify the prevailing anthelmintic drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the anthelmintic drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global anthelmintic drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market SegmentsBy Drug ClassBenzimidazoles
Macrocyclic Lactones
Pyrazinoisoquinolones
Tetrahydropyrimidines
Others
By Infection TypeCestode Infections
Nematode Infections
Trematode Infections
Mixed Infections
By Distribution ChannelOnline Providers
Hospital Pharmacies
Drug Stores and Retail Pharmacies
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market PlayersGlaxoSmithKline plc
Johnson & Johnson
Cipla Ltd.
Teva Pharmaceutical Industries Limited
Zydus Lifesciences Limited
Amneal Pharmaceuticals LLC
Merck & Co., Inc.
Sun Pharmaceutical Industries Ltd.
Reese Pharmaceutical Company
Bayer AG
Please Note: It will take 7-10 business days to complete the report upon order confirmation.